Clinical Studies Actively Recruiting Patients

Our two lead clinical studies are recruiting patients. If you have pruritus due to prurigo nodularis (PN) or chronic cough due to idiopathic pulmonary fibrosis (IPF) click the buttons below to see if you qualify.

A Potential New Hope for Patients with Chronic CNS Symptoms – Haduvio™

Are you suffering from or caring for someone with symptoms associated with chronic neurologically mediated conditions?

Trevi is developing the investigational therapy Haduvio™ (nalbuphine ER) as an oral treatment for a range of indications for which patients have few, if any, treatment options. With its dual mechanism of action, Haduvio™ has the potential to significantly improve the quality of life of patients with a broad range of neurologically mediated conditions.

For what indications is Haduvio™ being developed?

We are currently investigating the use of Haduvio™ in patients with:

    • Pruritus in Prurigo Nodularis – a chronic, intensely pruritic dermatological condition characterized by the presence of pruriginous lesions such as papules, nodules or plaques, which may be associated with excoriations and ulcerations. See if you qualify today!
    • Chronic Cough related to Idiopathic Pulmonary Fibrosis (IPF) – IPF is a rare, chronic, progressive lung disease, characterized by scarring and thickening of lung tissue; most patients diagnosed with IPF suffer from a dry, non-productive chronic cough that interrupts their daily living and significantly contributes to poor quality of life. Find a local study site near you!
    • Pruritus in Chronic Liver Disease – a common complication of chronic cholestatic liver diseases such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC); patients develop severe whole-body itch, an intense, intractable, debilitating condition that significantly disrupts patients’ daily activities and sleep, and consequently impairs their quality of life.

And are planning future clinical trials in patients with:

    • Levodopa-induced Dyskinesia (LID) in patients with Parkinson’s Disease – involuntary / motor complications resulting from levodopa therapy.
How can I stay informed on progress being made with Haduvio™?
Please visit our News page for the latest Trevi developments.

You can also follow our clinical progress on the website by typing Trevi Therapeutics into the “Other terms” search box.

How can I get involved in a clinical trial?

Email us at:

The PRISM trial is a medical research study of an investigational medication for people who have chronic, severely itchy bumps on their skin (also known as Prurigo Nodularis). Actively recruiting in the United States, Germany, Poland, Austria, and France. See if you pre-qualify.

The CANAL trial is a clinical research study looking at how an investigational study drug works on cough in people with idiopathic pulmonary fibrosis (IPF). Actively recruiting in the United Kingdom. Learn more –

Contact your physician to inquire about clinical trials available in your area.

Is expanded access available?

Randomized trials to assess the safety and efficacy of NAL ER are ongoing.  The goal of these studies is to understand the potential benefits, risks, and appropriate use(s) of NAL ER.   In order to participate, patients entering the clinical trials are required to meet specific criteria in order to protect their safety as well as the integrity of the trial. At this stage of development, Trevi considers that our current clinical trials provide the most appropriate path for patients to access the investigational medicine that we are developing.  As such, expanded access outside of the ongoing clinical trials is not currently available.

Note: Haduvio™ is an investigational therapy and not yet approved for use.